Pulmonary Sarcoidosis clinical trials

Explore recruiting pulmonary sarcoidosis clinical trials.

Recruiting pulmonary sarcoidosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pulmonary Sarcoidosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of a 12-week administration of OATD-01, an oral inhibitor of chitinase-1 (CHIT1), for the treatment of active pulmonary sarcoidosis (the KITE study)

Denmark, Germany, Greece, Poland, Norway, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of a 12-week administration of OATD-01, an oral inhibitor of chitinase-1 (CHIT1), for the treatment of active pulmonary sarcoidosis (the KITE study)

Germany, France, Greece, Denmark, Norway, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS EFZOFITIMOD IN PATIENTS WITH PULMONARY SARCOIDOSIS

France, Netherlands, Spain, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis - A randomized controlled trial

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A seamless, phase 1b/2 multiple ascending dose/proof of concept study of XTMAB-16 in patients with pulmonary sarcoidosis with or without extrapulmonary manifestations

Poland, Italy, Denmark, Spain, Czechia

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A seamless, phase 1b/2 multiple ascending dose/proof of concept study of XTMAB-16 in patients with pulmonary sarcoidosis with or without extrapulmonary manifestations

Spain, Czechia, Poland, Denmark, Greece, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Pulmonary Sarcoidosis trials by city

Pulmonary Sarcoidosis in Toronto Pulmonary Sarcoidosis in Vancouver Pulmonary Sarcoidosis in Montreal Pulmonary Sarcoidosis in Calgary Pulmonary Sarcoidosis in Edmonton Pulmonary Sarcoidosis in Ottawa Pulmonary Sarcoidosis in Winnipeg Pulmonary Sarcoidosis in Quebec City Pulmonary Sarcoidosis in Hamilton Pulmonary Sarcoidosis in Kitchener Pulmonary Sarcoidosis in London Pulmonary Sarcoidosis in Halifax Pulmonary Sarcoidosis in New York Pulmonary Sarcoidosis in Los Angeles Pulmonary Sarcoidosis in Chicago Pulmonary Sarcoidosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease